Phemerazole

Phemerazole
Clinical data
Other names	Phemerazol; Femerazol; Femerazole; Phenylmethylpyrazole; 3-Methyl-5-phenylpyrazole
Drug class	Sedative; Hypnotic; Anticonvulsant; Muscle relaxant; Mammary stimulant
ATC code	None;
Identifiers
	IUPAC name 5-methyl-3-phenyl-1H-pyrazole;
CAS Number	3347-62-4;
PubChem CID	18774;
ChemSpider	17727;
UNII	0XFX19D77A;
ChEMBL	ChEMBL1411986;
CompTox Dashboard (EPA)	DTXSID90187117 ;
ECHA InfoCard	100.020.091
Chemical and physical data
Formula	C10H10N2
Molar mass	158.204 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=NN1)C2=CC=CC=C2;
	InChI InChI=1S/C10H10N2/c1-8-7-10(12-11-8)9-5-3-2-4-6-9/h2-7H,1H3,(H,11,12); Key:QHRSESMSOJZMCO-UHFFFAOYSA-N;

Phemerazole, or femerazol, also known as 5-phenyl-3-methylpyrazole, is a sedative drug and aryl pyrazole derivative. It produces sedative, hypnotic, hypolocomotive, antiaggressive, anticonvulsant, muscle relaxant, and hypothermic effects in animals. In addition to its central nervous system effects, the drug has been found to potentiate the effects of diethylstilbestrol on the mammary glands in animals, including producing ductal and alveolar hyperplasia, stromal hyperemia, and lactogenesis. Its effects in this regard were said to resemble those of the sedative prolactin releasers chlorpromazine and reserpine. The exact mechanisms of action of phemerazole in terms of its various effects do not appear to be known. Phemerazole was first described in the scientific literature by 1960. Various active analogues and derivatives of phemerazole are known.